Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senators Willing To Negotiate On Patent Reform Bill Damage Provisions

This article was originally published in The Pink Sheet Daily

Executive Summary

Senate bill introduced March 3 includes some flexibility for the court to hear expert testimony to aid damage determinations and to consider unspecified “additional factors,” if appropriate.

You may also be interested in...



Proposed Patent Reform Bill Would Codify Georgia-Pacific Factors

Sen. Jon Kyl, R-Ariz., plans to soon introduce a patent damages bill that does not include the apportionment provisions opposed by the medical device industry and contained in legislation sponsored by Sen. Patrick Leahy (S. 1145)

Patent Bill Damages Provision Still Up For Debate – Senate Committee Report

A Senate Judiciary Committee 1report on a pending patent reform bill suggests a controversial provision on calculating infringement damages is still ripe for revision, but bill authors will not stray too far from their original intent

Patent Reform Amendments Don’t Satisfy Opponents, But Mark-Up Continues

Device stakeholders say revisions made to patent reform legislation in the Senate Judiciary Committee July 12 do not go far enough to address their concerns, but committee members' willingness to consider the issues further is encouraging

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel